Drug General Information
Drug ID	D05HTS
Former ID	DIB012524
Drug Name	PLX8394
Indication	Melanoma [ICD9: 172; ICD10:C43]		Phase 1/2	[525176]
Company	Daiichi sankyo parsippany
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	B-Raf proto-oncogene serine/threonine-protein kinase	Target Info	Inhibitor	[532568]
KEGG Pathway	MAPK signaling pathway
	ErbB signaling pathway
	Rap1 signaling pathway
	cAMP signaling pathway
	Chemokine signaling pathway
	FoxO signaling pathway
	mTOR signaling pathway
	Vascular smooth muscle contraction
	Focal adhesion
	Natural killer cell mediated cytotoxicity
	Long-term potentiation
	Neurotrophin signaling pathway
	Serotonergic synapse
	Long-term depression
	Regulation of actin cytoskeleton
	Insulin signaling pathway
	Progesterone-mediated oocyte maturation
	Alcoholism
	Hepatitis C
	Pathways in cancer
	Proteoglycans in cancer
	Colorectal cancer
	Renal cell carcinoma
	Pancreatic cancer
	Endometrial cancer
	Glioma
	Prostate cancer
	Thyroid cancer
	Melanoma
	Bladder cancer
	Chronic myeloid leukemia
	Acute myeloid leukemia
	Non-small cell lung cancer
NetPath Pathway	IL-7 Signaling Pathway
PANTHER Pathway	Angiogenesis
	Integrin signalling pathway
	Interleukin signaling pathway
	PDGF signaling pathway
	T cell activation
	VEGF signaling pathway
	Ras Pathway
	CCKR signaling map ST
Pathway Interaction Database	CDC42 signaling events
	mTOR signaling pathway
	Ras signaling in the CD4+ TCR pathway
	ErbB1 downstream signaling
	PDGFR-beta signaling pathway
	Signaling events mediated by VEGFR1 and VEGFR2
	Trk receptor signaling mediated by the MAPK pathway
PathWhiz Pathway	Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
	Intracellular Signalling Through Adenosine Receptor A2b and Adenosine
Reactome	Spry regulation of FGF signaling
	Frs2-mediated activation
	ARMS-mediated activation
	CREB phosphorylation through the activation of Ras
	RAF activation
	MAP2K and MAPK activation
	Negative feedback regulation of MAPK pathway
	Negative regulation of MAPK pathway
WikiPathways	Serotonin Receptor 4/6/7 and NR3C Signaling
	Serotonin HTR1 Group and FOS Pathway
	Estrogen signaling pathway
	Senescence and Autophagy in Cancer
	Regulation of Actin Cytoskeleton
	EGF/EGFR Signaling Pathway
	MAPK Cascade
	MAPK Signaling Pathway
	Focal Adhesion
	Bladder Cancer
	Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
	Polycystic Kidney Disease Pathway
	Corticotropin-releasing hormone
	B Cell Receptor Signaling Pathway
	Signaling Pathways in Glioblastoma
	TSH signaling pathway
	Integrated Breast Cancer Pathway
	Signaling by FGFR
	NGF signalling via TRKA from the plasma membrane
	Integrin-mediated Cell Adhesion
References
Ref 525176	ClinicalTrials.gov (NCT02428712) A Study of PLX8394 as a Single Agent in Patients With Advanced, Unresectable Solid Tumors. U.S. National Institutes of Health.
Ref 532568	Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors. Pigment Cell Melanoma Res. 2014 Mar;27(2):253-62.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.